Praxis Precision Medicines, Inc.
relutrigine
broad DEEs
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for relutrigine in broad DEEs are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Recruiting completed for relutrigine EMERALD study in broad DEEs, with topline results expected in Q4 2026”